Developer docs
API playgroundTry for free, no card

Search company profiles

Holobiome

Full company profile

uuid0004bky

Namestring
Holobiome
Legal namestring
Holobiome Inc.
Websiteurl
holobiome.org
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Holobiome is a privately held microbiome therapeutics company founded in 2015 by Northeastern University researchers Philip Strandwitz and Kim Lewis, headquartered at 650 Albany Street in Boston. The company operates a microbial discovery platform consisting of a large proprietary bacterial strain library, proprietary culturomics methods designed to isolate representatives of every known gut bacterial species, and mechanism-of-action-focused screening capabilities. The platform is supported by gut behavior profiles from over 90,000 people and a reference database of more than 2 million gut bacterial genomes, augmented by an Asian donor network of more than 8,000 participants acquired through the 2022 purchase of AsiaBiome.

Holobiome's product pipeline targets the gut-brain axis with three primary programs: a depression probiotic advancing toward human testing (funded by the 2024 $9M seed round), gut-pain axis microbial therapies (supported by $1M from Japan's Corundum Systems Biology), and live biotherapeutics for sleep disorders developed in partnership with Johnson & Johnson. The company has also secured participation in the ARPA-H EVIDENT $139 million behavioral health initiative and a $500K grant from the Translational Research Institute for Space Health for mental health probiotics targeting future Mars explorers.

The business model is enterprise B2B, monetized through live biotherapeutic licensing, ingredient discovery partnerships, and bacterial strain catalog transactions with pharmaceutical and food/beverage counterparties. Named enterprise partners include Johnson & Johnson (sleep live biotherapeutics), Unilever (food portfolio microbiome products), and Ingredion (AI-driven ingredient discovery for prebiotics). With 1-10 employees, pre-clinical pipeline status, and approximately $10M in cumulative funding, the company operates as an early-stage biotech leveraging grant funding and milestone-based partnerships rather than commercial product revenue.

Short descriptiontext

Holobiome is a microbiome therapeutics company developing first-in-class gut-brain axis therapies for depression, sleep disorders, and pain through a proprietary bacterial strain library and culturomics platform, serving pharmaceutical and food/beverage enterprises via licensing and co-development partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microbiome therapeutics, live biotherapeutics, gut-brain axis, probiotic development, microbial strain library
Industry5 codes
PRIMARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
SECONDARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAGANAH
Microbiome & Metagenomics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYAFAJAKAE
Probiotics (Strains, Spore-Formers, Synbiotic Components)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)
SECONDARYCRADAGAF
Probiotics & Digestive Health Supplements
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Microbiome Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Live Biotherapeutic Licensing
TypeLicensing Royalties
Description

Development and licensing of probiotic and live biotherapeutic products targeting conditions such as depression, sleep disorders, and pain. The company is advancing programs into human testing and pursuing partnerships with pharmaceutical companies for clinical development and commercialization.

holobiome.org
2Ingredient Discovery Partnership
TypeProfessional Services
Description

Collaboration with Ingredion to provide AI-driven gut behavior analysis and ingredient discovery services for functional food and prebiotic ingredients. Partnerships designed to integrate AI throughout food manufacturers' reformulation processes.

indexbox.io
3Bacterial Strain Catalog
TypeTransaction Fee
Description

Commercialization of characterized bacterial strains and microbial libraries to research institutions, pharmaceutical companies, and food companies seeking to develop microbiome-based products.

holobiome.org
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Holobiome discovers and develops first-in-class microbiome-based therapies, including live biotherapeutic candidates for depression, sleep disorders, and chronic pain, leveraging its proprietary culturomics platform and large bacterial strain library. The company also provides AI-driven gut behavior analysis and ingredient discovery capabilities to food and ingredient manufacturers such as Unilever and Ingredion, and pursues clinical development and commercialization through pharmaceutical co-development partners such as Johnson & Johnson.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Platform screens gut behavior using profiles from 90,000+ people and 2M+ bacterial genomes
Product overview1 text field

Holobiome is a microbiome science company that discovers and develops first-in-class therapies from the human microbiome. The company operates a unified platform consisting of a large bacterial strain library, proprietary culturomics, and advanced screening and development methods. The platform powers multiple therapeutic programs including a depression probiotic (advancing to human testing), pain/gut-pain axis solutions, and sleep disorder live biotherapeutics (developed with Johnson & Johnson). Holobiome's platform generates insights using profiles from over 90,000 people and a database of more than 2 million gut bacterial genomes, enabling AI-powered ingredient discovery for functional foods and therapeutics targeting the gut-brain axis.

Product and service4 records
1Depression Probiotic
CategoryMicrobiome Therapeutics
Description

A live biotherapeutic / probiotic candidate targeting depression, developed through Holobiome's gut-brain axis platform and advancing toward human clinical testing. Intended for pharmaceutical partners and ultimately for patients with depression.

2Sleep Disorder Live Biotherapeutics
CategoryMicrobiome Therapeutics
Description

Live biotherapeutic candidates for sleep disorders developed in partnership with Johnson & Johnson Innovation and Janssen R&D. Aimed at addressing unmet needs in sleep medicine through microbiome-based interventions.

3Pain / Gut-Pain Axis Therapies
CategoryMicrobiome Therapeutics
Description

Microbial therapies for chronic pain and inflammation-related diseases, developed by studying the gut microbiome's role in pain regulation. Funded by a $1M research grant from Corundum Systems Biology Inc.

4Gut Behavior Analysis Platform
CategoryMicrobiome Intelligence / AI Analytics
Description

An AI-driven analysis platform that generates insights on ingredient behavior in the gut, using profiles from over 90,000 people and a reference database of more than 2 million gut bacterial genomes. Provided to food and ingredient manufacturers such as Ingredion and Unilever to support functional ingredient development and reformulation.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-18
Description

Partnership to accelerate discovery of new food ingredients focusing on prebiotics and gut behavior analysis. Holobiome's platform generates insights on gut behavior using profiles from over 90,000 people and a database of more than 2 million gut bacterial genomes. The collaboration integrates AI throughout Ingredion's reformulation process for functional ingredients.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-07-25
Description

Featured collaborator for Unilever to transform its food portfolio with microbiome products and advance one program into human testing. Partnership leverages Holobiome's microbiome expertise and proprietary microbial library for consumer health applications.

3AsiaBiome
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-15
Description

Holobiome acquired AsiaBiome (formerly Civet Biosciences, founded 2016 in Hong Kong), Asia's first microbiome startup. The acquisition includes a human microbiome donor network of more than 8,000 participants in Asia, fecal transplant study data, and expanded bacterial strain collection. Co-founder Jonathan Krive joined Holobiome as Chief Business Officer. Deal included cash, milestone and royalty payments, and equity.

holobiome.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

J&J Consumer, J&J Innovation, and Janssen R&D announced partnership with Holobiome to develop live biotherapeutics for sleep disorders. The collaboration represents one of 15 new collaborations with Holobiome. A second collaboration was also announced to create novel microbiome therapeutics.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
14D pharma
TypeDirect peer
Description

Clinical-stage microbiome company developing live biotherapeutics (single-strain and consortium approaches) across oncology, respiratory, and CNS-adjacent indications. Direct peer in live biotherapeutic development with a comparable platform-discovery model.

2Second Genome
TypeDirect peer
Description

Microbiome drug discovery and development company using a platform approach to identify microbiome-derived therapeutics. Comparable in platform-driven discovery model and pursuit of CNS-adjacent and inflammatory indications.

TypeEmerging player
Description

Clinical-stage company developing live biotherapeutics for inflammatory diseases including asthma and allergic disease. Adjacent peer with comparable live biotherapeutic development model and academic-spinout origin.

TypeEmerging player
Description

Biotechnology company with a microbiome program developing live biotherapeutics for conditions associated with liver disease and inflammation. Comparable in live biotherapeutic development with a partnership-driven model.

TypeEmerging player
Description

Microbiome science company developing consumer probiotics and B2B microbial applications. Comparable in the platform-plus-partnerships model and gut-brain axis focus, though more consumer-facing than Holobiome's pharma orientation.

TypeEmerging player
Description

Biotechnology company developing engineered microbiome-based therapeutics using synthetic biology. Adjacent peer with overlap in microbiome-based drug development, though focused on phage-delivered gene therapy rather than live biotherapeutics.

7BioGaia
TypeBroad incumbent
Description

Established Swedish probiotics company with a broad portfolio of probiotic consumer health products and a licensed pharmaceutical pipeline. Comparable in probiotic strain commercialization and gut health focus, though primarily CPG rather than pharma-led.

TypeDirect peer
Description

Clinical-stage microbiome therapeutics company developing live biotherapeutics for serious diseases. Direct competitor in the live biotherapeutic product category with overlapping interest in CNS-adjacent indications, though Seres has historically focused more on ulcerative colitis and C. difficile.

TypeDirect peer
Description

Microbiome therapeutics company developing treatments for recurrent C. difficile infection and other conditions using defined microbial consortia. Direct peer in live biotherapeutics, though Finch has focused more on inflammatory bowel and CDI rather than CNS.

TypeDirect peer
Description

Clinical-stage company developing defined bacterial consortia as live biotherapeutic products. Direct competitor in microbiome therapeutics with similar platform-based discovery approach and pharma partnership model, including programs in inflammatory and infectious disease indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Holobiome

Microbiome Therapeuticsholobiome.org

Holobiome is a microbiome therapeutics company developing first-in-class gut-brain axis therapies for depression, sleep disorders, and pain through a proprietary bacterial strain library and culturomics platform, serving pharmaceutical and food/beverage enterprises via licensing and co-development partnerships.

What Holobiome does

Holobiome is a privately held microbiome therapeutics company founded in 2015 by Northeastern University researchers Philip Strandwitz and Kim Lewis, headquartered at 650 Albany Street in Boston. The company operates a microbial discovery platform consisting of a large proprietary bacterial strain library, proprietary culturomics methods designed to isolate representatives of every known gut bacterial species, and mechanism-of-action-focused screening capabilities. The platform is supported by gut behavior profiles from over 90,000 people and a reference database of more than 2 million gut bacterial genomes, augmented by an Asian donor network of more than 8,000 participants acquired through the 2022 purchase of AsiaBiome.

Holobiome's product pipeline targets the gut-brain axis with three primary programs: a depression probiotic advancing toward human testing (funded by the 2024 $9M seed round), gut-pain axis microbial therapies (supported by $1M from Japan's Corundum Systems Biology), and live biotherapeutics for sleep disorders developed in partnership with Johnson & Johnson. The company has also secured participation in the ARPA-H EVIDENT $139 million behavioral health initiative and a $500K grant from the Translational Research Institute for Space Health for mental health probiotics targeting future Mars explorers.

The business model is enterprise B2B, monetized through live biotherapeutic licensing, ingredient discovery partnerships, and bacterial strain catalog transactions with pharmaceutical and food/beverage counterparties. Named enterprise partners include Johnson & Johnson (sleep live biotherapeutics), Unilever (food portfolio microbiome products), and Ingredion (AI-driven ingredient discovery for prebiotics). With 1-10 employees, pre-clinical pipeline status, and approximately $10M in cumulative funding, the company operates as an early-stage biotech leveraging grant funding and milestone-based partnerships rather than commercial product revenue.

Holobiome firmographics

Firmographics
Name
Holobiome
Legal name
Holobiome Inc.
Website
https://holobiome.org
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Holobiome is a microbiome therapeutics company developing first-in-class gut-brain axis therapies for depression, sleep disorders, and pain through a proprietary bacterial strain library and culturomics platform, serving pharmaceutical and food/beverage enterprises via licensing and co-development partnerships.
Ownership category
akta.pro rank

Holobiome industry classification

Industry
Product category
Microbiome Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
SECONDARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAGANAH
Microbiome & Metagenomics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYAFAJAKAE
Probiotics (Strains, Spore-Formers, Synbiotic Components)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)
SECONDARYCRADAGAF
Probiotics & Digestive Health Supplements

Keywords

  • Microbiome therapeutics
  • Live biotherapeutics
  • Gut-brain axis
  • Probiotic development
  • Microbial strain library

Where Holobiome is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Holobiome business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Live Biotherapeutic Licensing: Development and licensing of probiotic and live biotherapeutic products targeting conditions such as depression, sleep disorders, and pain. The company is advancing programs into human testing and pursuing partnerships with pharmaceutical companies for clinical development and commercialization.
  2. Ingredient Discovery Partnership: Collaboration with Ingredion to provide AI-driven gut behavior analysis and ingredient discovery services for functional food and prebiotic ingredients. Partnerships designed to integrate AI throughout food manufacturers' reformulation processes.
  3. Bacterial Strain Catalog: Commercialization of characterized bacterial strains and microbial libraries to research institutions, pharmaceutical companies, and food companies seeking to develop microbiome-based products.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Holobiome product offering

Product offering

Core offering

Holobiome discovers and develops first-in-class microbiome-based therapies, including live biotherapeutic candidates for depression, sleep disorders, and chronic pain, leveraging its proprietary culturomics platform and large bacterial strain library. The company also provides AI-driven gut behavior analysis and ingredient discovery capabilities to food and ingredient manufacturers such as Unilever and Ingredion, and pursues clinical development and commercialization through pharmaceutical co-development partners such as Johnson & Johnson.

Product overview

Holobiome is a microbiome science company that discovers and develops first-in-class therapies from the human microbiome. The company operates a unified platform consisting of a large bacterial strain library, proprietary culturomics, and advanced screening and development methods. The platform powers multiple therapeutic programs including a depression probiotic (advancing to human testing), pain/gut-pain axis solutions, and sleep disorder live biotherapeutics (developed with Johnson & Johnson). Holobiome's platform generates insights using profiles from over 90,000 people and a database of more than 2 million gut bacterial genomes, enabling AI-powered ingredient discovery for functional foods and therapeutics targeting the gut-brain axis.

Differentiator

Problem solved

Functional benefit

Products and services

  • Depression Probiotic A live biotherapeutic / probiotic candidate targeting depression, developed through Holobiome's gut-brain axis platform and advancing toward human clinical testing. Intended for pharmaceutical partners and ultimately for patients with depression.
  • Sleep Disorder Live Biotherapeutics Live biotherapeutic candidates for sleep disorders developed in partnership with Johnson & Johnson Innovation and Janssen R&D. Aimed at addressing unmet needs in sleep medicine through microbiome-based interventions.
  • Pain / Gut-Pain Axis Therapies Microbial therapies for chronic pain and inflammation-related diseases, developed by studying the gut microbiome's role in pain regulation. Funded by a $1M research grant from Corundum Systems Biology Inc.
  • Gut Behavior Analysis Platform An AI-driven analysis platform that generates insights on ingredient behavior in the gut, using profiles from over 90,000 people and a reference database of more than 2 million gut bacterial genomes. Provided to food and ingredient manufacturers such as Ingredion and Unilever to support functional ingredient development and reformulation.

Quantifiable outcome

  • Platform screens gut behavior using profiles from 90,000+ people and 2M+ bacterial genomes

Companies that use Holobiome

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Holobiome technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Holobiome partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • IngredioncoreStrategic or Co-development Partner · 18 March 2026Partnership to accelerate discovery of new food ingredients focusing on prebiotics and gut behavior analysis. Holobiome's platform generates insights on gut behavior using profiles from over 90,000 people and a database of more than 2 million gut bacterial genomes. The collaboration integrates AI throughout Ingredion's reformulation process for functional ingredients.
  • UnilevercoreStrategic or Co-development Partner · 25 July 2023Featured collaborator for Unilever to transform its food portfolio with microbiome products and advance one program into human testing. Partnership leverages Holobiome's microbiome expertise and proprietary microbial library for consumer health applications.
  • AsiaBiomecoreStrategic or Co-development Partner · 15 November 2022Holobiome acquired AsiaBiome (formerly Civet Biosciences, founded 2016 in Hong Kong), Asia's first microbiome startup. The acquisition includes a human microbiome donor network of more than 8,000 participants in Asia, fecal transplant study data, and expanded bacterial strain collection. Co-founder Jonathan Krive joined Holobiome as Chief Business Officer. Deal included cash, milestone and royalty payments, and equity.
  • Johnson & Johnson InnovationcoreStrategic or Co-development PartnerJ&J Consumer, J&J Innovation, and Janssen R&D announced partnership with Holobiome to develop live biotherapeutics for sleep disorders. The collaboration represents one of 15 new collaborations with Holobiome. A second collaboration was also announced to create novel microbiome therapeutics.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Holobiome competitors and assessment

Company assessment

Direct peers

  • 4D pharma: Clinical-stage microbiome company developing live biotherapeutics (single-strain and consortium approaches) across oncology, respiratory, and CNS-adjacent indications. Direct peer in live biotherapeutic development with a comparable platform-discovery model.
  • Second Genome: Microbiome drug discovery and development company using a platform approach to identify microbiome-derived therapeutics. Comparable in platform-driven discovery model and pursuit of CNS-adjacent and inflammatory indications.
  • Seres Therapeutics: Clinical-stage microbiome therapeutics company developing live biotherapeutics for serious diseases. Direct competitor in the live biotherapeutic product category with overlapping interest in CNS-adjacent indications, though Seres has historically focused more on ulcerative colitis and C. difficile.
  • Finch Therapeutics: Microbiome therapeutics company developing treatments for recurrent C. difficile infection and other conditions using defined microbial consortia. Direct peer in live biotherapeutics, though Finch has focused more on inflammatory bowel and CDI rather than CNS.
  • Vedanta Biosciences: Clinical-stage company developing defined bacterial consortia as live biotherapeutic products. Direct competitor in microbiome therapeutics with similar platform-based discovery approach and pharma partnership model, including programs in inflammatory and infectious disease indications.

Emerging players

  • Siolta Therapeutics: Clinical-stage company developing live biotherapeutics for inflammatory diseases including asthma and allergic disease. Adjacent peer with comparable live biotherapeutic development model and academic-spinout origin.
  • Assembly Biosciences: Biotechnology company with a microbiome program developing live biotherapeutics for conditions associated with liver disease and inflammation. Comparable in live biotherapeutic development with a partnership-driven model.
  • Seed Health: Microbiome science company developing consumer probiotics and B2B microbial applications. Comparable in the platform-plus-partnerships model and gut-brain axis focus, though more consumer-facing than Holobiome's pharma orientation.
  • Eligo Bioscience: Biotechnology company developing engineered microbiome-based therapeutics using synthetic biology. Adjacent peer with overlap in microbiome-based drug development, though focused on phage-delivered gene therapy rather than live biotherapeutics.

Broad incumbents

  • BioGaia: Established Swedish probiotics company with a broad portfolio of probiotic consumer health products and a licensed pharmaceutical pipeline. Comparable in probiotic strain commercialization and gut health focus, though primarily CPG rather than pharma-led.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Holobiome social profiles

Digital presence

Holobiome financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Holobiome leadership team

Management profile

Number of profiles

Profiles6 records

Holobiome subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Holobiome funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Holobiome M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Holobiome

What does Holobiome do?

Holobiome discovers and develops first-in-class microbiome-based therapies, including live biotherapeutic candidates for depression, sleep disorders, and chronic pain, leveraging its proprietary culturomics platform and large bacterial strain library. The company also provides AI-driven gut behavior analysis and ingredient discovery capabilities to food and ingredient manufacturers such as Unilever and Ingredion, and pursues clinical development and commercialization through pharmaceutical co-development partners such as Johnson & Johnson.

Is Holobiome a public or private company?

Holobiome is a private company. It is classified as venture growth investor backed and is currently operating.

When was Holobiome founded?

Holobiome was founded in 2015. It employs 11 to 50 people.

Where is Holobiome based?

Holobiome is headquartered in Boston, United States, in the North America region.

How does Holobiome make money?

Three revenue lines are on record. Live Biotherapeutic Licensing is the primary driver. The others are ingredient Discovery Partnership and bacterial Strain Catalog.

Who are Holobiome's main competitors?

Direct peers on record are 4D pharma, Second Genome, Seres Therapeutics, Finch Therapeutics and Vedanta Biosciences. Emerging players are Siolta Therapeutics, Assembly Biosciences, Seed Health and Eligo Bioscience. BioGaia is listed as a broad incumbent.

Does Holobiome have an API?

No public API is recorded for Holobiome.

What industry is Holobiome in?

Holobiome's product category is Microbiome Therapeutics. Its primary akta.pro industry code is HLAAAFAJ, Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery), with a secondary code of HLAAAFAI, Microbiome Analytics, Sequencing & Bioinformatics Platforms. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageHolobiome and Radicle Science Launch U.S. History’s Largest Mental Wellness Trial Targeting the Gut-Brain AxisHolobiome and Radicle Science launched GUT-FEELINGS, a two-year ARPA-H-backed trial enrolling over 6,000 Americans to test 19 prebiotic formulas against placebo for anxiety and mental wellness. The study will collect over 24,000 fecal and 12,000 blood samples, with initial results expected in the second half of 2027.nutraingredients.comProbiota Pioneer: Holobiome on building the infrastructure to decipher the madness of the microbiomeHolobiome, a Boston-based life sciences company founded by Northeastern University researchers, is building the world's largest cultured collection of human gut bacteria and associated data infrastructure to support microbiome research. The company has announced collaborative R&D engagements with major industry partners including Kenvue, Unilever, Ingredion, and AstraZeneca to develop precision probiotics and live biotherapeutics. Holobiome is currently launching large-scale interventional trials involving over 6,000 participants to validate its platform-driven approach to microbiome modulation.nutraingredients.comMeet the 2026 Probiota Pioneers: ClostraBio, Holobiome and KiogaClostraBio, Holobiome, and Kioga have been selected as the 2026 Probiota Pioneers to showcase their microbiome science innovations at the upcoming Probiota Americas conference in Vancouver. ClostraBio is advancing its butyrate-delivery product CLB101 with a global distribution partnership and clinical trials, while Holobiome focuses on precision therapeutics for depression using its extensive microbial genome vault. Kioga is developing postbiotic ingredients targeting stress resilience and neuro-immune balance through its NeuroAlly platform.IndexBoxIngredion Partners with Shiru & Holobiome for Faster Ingredient DiscoveryIngredion is collaborating with technology companies Shiru and Holobiome to accelerate the discovery of new food ingredients, focusing on prebiotics and gut behavior analysis. These partnerships aim to enhance Ingredion's capability to develop functional ingredients with increased confidence, addressing market demands for health benefits and ingredient transparency.Pulse 2.0Holobiome: Microbiome Platform Company Raises $9 Million (Seed)Holobiome closed a $9 million seed round led by iSelect Fund, with participation from Corundum Systems Biology, Satori Neuro, and others. The company will use the funding to advance its lead depression-targeting probiotic into human testing and expand its microbiome platform. The round also brings three new board members, including Dr. Joan LaRovere and Dr. Iain Chessell.YahooHolobiome, a Microbiome Platform Startup Targeting the Gut-Brain-Axis, Closes Oversubscribed Seed RoundHolobiome closed an oversubscribed $9M seed round led by iSelect Fund, with participation from Corundum Systems Biology, Satori Neuro, and others. The company will use the capital to advance its lead depression-targeting probiotic into human testing and expand its platform. The funding also brings new board members, including Joan LaRovere and Iain Chessell.PR NewswireHolobiome, a Microbiome Platform Startup Targeting the Gut-Brain-Axis, Closes Oversubscribed Seed RoundHolobiome closed a $9M oversubscribed seed round led by iSelect Fund, with participation from Corundum Systems Biology, Satori Neuro, and others. The company will use the capital to advance its lead depression-targeting probiotic into human testing and expand its microbiome platform. The funding also brings new board members, including Dr. Joan LaRovere and Dr. Iain Chessell.FinSMEsHolobiome Closes Seed FundingHolobiome, a Boston-based biotechnology company, closed a seed funding round led by iSelect Fund with participation from several other investors including Valor Equity Partners and Astanor. The company plans to use the capital to advance its lead probiotic program for depression into human testing and expand its analytical pipelines. Additionally, Dr. Joan LaRovere will join Holobiome's board of directors as part of the transaction.SecSEC FORM DHolobiome, Inc. filed a Form D with the SEC for an exempt securities offering under Regulation D Rule 506(b), with total proceeds of $9,361,054 and $6,590,554 already sold as of March 2024. The filing indicates the company is in the biotechnology sector, based in Delaware with operations in Massachusetts.PR NewswireMICROBIOME PLATFORM COMPANY HOLOBIOME ANNOUNCES COLLABORATION TO DEVELOP PRODUCTS FOR INFANT AND MATERNAL HEALTHHolobiome announced a research collaboration with Johnson & Johnson Consumer Inc. to develop next-generation probiotics and prebiotics targeting infant and maternal immune health. The partnership leverages Holobiome's Microbiome Vault platform, which utilizes samples from over 9,000 donors to identify beneficial bacteria for specific biological pathways.